{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:31:37Z","timestamp":1785148297241,"version":"3.55.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,5]]},"DOI":"10.7759\/cureus.110321","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T23:15:39Z","timestamp":1780701339000},"source":"Crossref","is-referenced-by-count":1,"title":["Abiraterone-Induced Hypokalemia and Hypophosphatemia: A Case Report"],"prefix":"10.7759","author":[{"given":"Adnan","family":"Safi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Fayyaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fnu","family":"Veerban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Jahangir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari","family":"Vishal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Akatibo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gnama","family":"Kouyate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Mallappallil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Azhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA- 302): final overall survival analysis of a randomized, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan CJ","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, et al.. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA- 302): final overall survival analysis of a randomized, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015, 16:152-160. 10.1016\/S1470-2045(14)71205-7","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi K","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, et al.. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017, 377:352-60. 10.1056\/NEJMoa1704174","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.1281","article-title":"Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy","volume":"28","author":"Ryan CJ","year":"2010","unstructured":"Ryan CJ, Smith MR, Fong L, et al.. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010, 28:1481-8. 10.1200\/JCO.2009.24.1281","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.02.067","article-title":"Abiraterone acetate in the treatment of prostate cancer","volume":"101","author":"Thakur A","year":"2018","unstructured":"Thakur A, Roy A, Ghosh A, et al.. Abiraterone acetate in the treatment of prostate cancer. Biomed Pharmacother. 2018, 101:211-8. 10.1016\/j.biopha.2018.02.067","journal-title":"Biomed Pharmacother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1414395","article-title":"Serious hypokalemia associated with abiraterone acetate in patients with castration-resistant prostate cancer","volume":"2018","author":"Yamamoto Y","year":"2018","unstructured":"Yamamoto Y, Akashi Y, Minami T, et al.. Serious hypokalemia associated with abiraterone acetate in patients with castration-resistant prostate cancer. Case Rep Urol. 2018, 2018:1414395. 10.1155\/2018\/1414395","journal-title":"Case Rep Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42533","article-title":"Abiraterone-induced hypokalemia: a case report","volume":"15","author":"Nkwocha BI","year":"2023","unstructured":"Nkwocha BI, Singh M. Abiraterone-induced hypokalemia: a case report. Cureus. 2023, 15:e42533. 10.7759\/cureus.42533","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.23678","article-title":"A case of abiraterone-related hypokalemia leading to torsades de pointes and cardiac arrest","volume":"14","author":"Lee DH","year":"2022","unstructured":"Lee DH, Money DB, Deshpande A, Samuels B. A case of abiraterone-related hypokalemia leading to torsades de pointes and cardiac arrest. Cureus. 2022, 14:e23678. 10.7759\/cureus.23678","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/490728-abiraterone-induced-hypokalemia-and-hypophosphatemia-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T23:15:40Z","timestamp":1780701340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/490728-abiraterone-induced-hypokalemia-and-hypophosphatemia-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.110321","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,5]]}}}